Since 2020, when China’s Ministry of Commerce released a negative list for foreign investment prohibiting activities related to genetic diagnosis and cell and gene therapies (CGTs), there have no further implementation details about whether these would be deemed no-go zones for foreign pharma players.
This is what the European Chamber of Commerce in China, whose pharma working group represents roughly 40 overseas companies in the sector, is seeking to get clearer answers on